Clinuvel Pharmaceuticals Ltd

CUV

Company Profile

  • Business description

    Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

  • Contact

    535 Bourke Street
    Level 22
    MelbourneVIC3000
    AUS

    T: +61 396604900

    https://www.clinuvel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    16

Clinuvel Pharmaceuticals Ltd News & Analysis

stocks

Undervalued ASX biotech

Despite improving prospects the shares continue to sell off.
stocks

Undervalued ASX listed biotech refocuses

Fair value uneffected by suspended early-stage clinical trials.
funds

10 reasons many fund managers are now blank spaces

It looks easy from the outside, but asset management is a tough game. Winners can win big, but there are far more strugglers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,922.0077.00-0.86%
CAC 407,618.3072.140.96%
DAX 4023,741.61315.641.35%
Dow JONES (US)43,920.62210.36-0.48%
FTSE 1009,099.3433.47-0.37%
HKSE24,733.4539.88-0.16%
NASDAQ20,904.37254.241.23%
Nikkei 22540,290.70779.12-1.90%
NZX 50 Index12,684.04139.70-1.09%
S&P 5006,293.2555.240.89%
S&P/ASX 2008,663.7079.10-0.90%
SSE Composite Index3,583.3123.360.66%

Market Movers